An example of modification of the treatment targets are mutations of the EGFR ectodomain, which have been shown to generate secondary resistance to anti-EGFR monoclonal antibodies (mAbs) (i.e., rituximab) in CRC [13,14]. Here, EGFR is linked to colorectal carcinoma.